“Our desire is to increase our own knowledge of existing orphan medicines, driving innovation and improved treatments for patients.”
Chikai Lai, Operations and Programme Management
Quality of Life
We believe that the patient should come first, so we’re working with renowned partners and universities to reimagine how orphan drugs can benefit patients. Improving drugs means improving patients’ quality of life at every stage.
We ensure that decades of academic studies are translated into clinical research and product innovation. Working with our academic partners, we are able to address unexplored ways to improve patients’ conditions.
A NEW ERA OF CHOICE
Launched in 2016, NITYR (nitisinone) is our first commercial product and demonstrates the commitment we have to improving patients’ lives. NITYR contains the same nitisinone medication that Tyrosinaemia type 1 (HT-1) patients have always used, but has an improved formulation aiming to provide patients with greater convenience. Visit the US Website here.
NITYR is a registered trademark of Cycle Pharmaceuticals Limited in the United States